Clinical Trials
33 trialsNCT07570173 2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT03821246 2026-06-04
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
University of California, San Francisco
Phase 2 Recruiting
NCT05091424 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT05207670 2026-06-03
MorningSun
Genentech, Inc.
Phase 2 Active not recruiting
NCT05533775 2026-06-03
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05583617 2026-06-03
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05927571 2026-06-03
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06084936 2026-06-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06624085 2026-06-03
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT04077723 2026-05-29
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03448042 2026-05-28
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT07609940 2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4 Not yet recruiting
NCT03434730 2026-05-26
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05169515 2026-05-18
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT07594067 2026-05-18
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07589634 2026-05-15
TRI Pro
Janssen Research & Development, LLC
Phase 2 Not yet recruiting
NCT05646836 2026-05-14
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT06934044 2026-05-11
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05846789 2026-05-08
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Indiana University
Phase 2 Recruiting
NCT05171647 2026-05-07
SUNMO
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05535244 2026-05-07
CAMMA 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03075696 2026-04-30
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05233397 2026-04-23
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03533283 2026-04-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04246086 2026-03-19
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04910568 2026-03-19
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting